Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Hematologic and lymphatic disorders associated with chimeric antigen receptor T-cell therapy: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database

Fig. 5

Assessment of various hematologic and lymphatic system adverse events (AEs) associated with mortality after CAR-T therapy. A) Number and proportion of fatal reports for hematologic and lymphatic system AEs following treatment with different CAR-T products. B) Number of fatal reports and mortality rates for hematologic and lymphatic system AEs across different CAR-T products. C) K-fold cross-validation for selecting the optimal number of K-folds and Alpha parameter for LASSO regression

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us